XML 21 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid In Capital
AOCI
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   159,423,410      
Beginning balance at Dec. 31, 2020 $ 2,235,553 $ 1,595 $ 4,279,327 $ 526 $ (2,045,895)
Increase (Decrease) in Stockholders' Equity          
Conversion of convertible notes, net of tax (in shares)   580      
Exercise of common stock options (in shares)   1,295,104      
Exercise of common stock options 14,437 $ 13 14,424    
Issuance of common stock to fund the Company's 401(k) match (in shares)   162,606      
Issuance of common stock to fund the Company’s 2020 401(k) match 22,934 $ 2 22,932    
Compensation expense related to issuance of stock options and restricted stock awards (in shares)   1,879,169      
Compensation expense related to issuance of stock options and restricted stock awards 334,023 $ 19 334,004    
Purchase of employee stock purchase plan shares (in shares)   331,769      
Purchase of employee stock purchase plan shares 23,070 $ 3 23,067    
Issuance of common stock to fund business combinations (in shares)   10,581,429      
Replaced restricted stock awards for business combinations 1,355,170 $ 106 1,355,064    
Net loss (595,625)       (595,625)
Other comprehensive loss (1,969)     (1,969)  
Ending balance (in shares) at Dec. 31, 2021   173,674,067      
Ending balance at Dec. 31, 2021 3,387,636 $ 1,738 6,028,861 (1,443) (2,641,520)
Increase (Decrease) in Stockholders' Equity          
Conversion of convertible notes, net of tax 43   43    
Exercise of common stock options (in shares)   706,134      
Exercise of common stock options 6,524 $ 6 6,518    
Issuance of common stock to fund the Company's 401(k) match (in shares)   391,129      
Issuance of common stock to fund the Company’s 2020 401(k) match 29,202 $ 4 29,198    
Compensation expense related to issuance of stock options and restricted stock awards (in shares)   2,220,510      
Compensation expense related to issuance of stock options and restricted stock awards 206,823 $ 22 206,801    
Purchase of employee stock purchase plan shares (in shares)   668,605      
Purchase of employee stock purchase plan shares 25,491 $ 7 25,484    
Issuance of common stock to fund business combinations (in shares)   265,186      
Replaced restricted stock awards for business combinations 14,792 $ 3 14,789    
Other (7)   (7)    
Net loss (623,506)       (623,506)
Other comprehensive loss $ (3,793)     (3,793)  
Ending balance (in shares) at Dec. 31, 2022 177,925,631 177,925,631      
Ending balance at Dec. 31, 2022 $ 3,043,162 $ 1,780 6,311,644 (5,236) (3,265,026)
Increase (Decrease) in Stockholders' Equity          
Exercise of common stock options (in shares) 194,629 194,597      
Exercise of common stock options $ 3,197 $ 2 3,195    
Issuance of common stock to fund the Company's 401(k) match (in shares)   517,550      
Issuance of common stock to fund the Company’s 2020 401(k) match 35,100 $ 5 35,095    
Compensation expense related to issuance of stock options and restricted stock awards (in shares)   1,801,954      
Compensation expense related to issuance of stock options and restricted stock awards 231,312 $ 18 231,294    
Purchase of employee stock purchase plan shares (in shares)   924,448      
Purchase of employee stock purchase plan shares 28,344 $ 10 28,334    
Issuance of common stock to fund business combinations (in shares)   0      
Replaced restricted stock awards for business combinations 1,675 $ 0 1,675    
Net loss (204,149)       (204,149)
Other comprehensive loss $ 6,664     6,664  
Ending balance (in shares) at Dec. 31, 2023 181,364,180 181,364,180      
Ending balance at Dec. 31, 2023 $ 3,145,305 $ 1,815 $ 6,611,237 $ 1,428 $ (3,469,175)